Copyright
©The Author(s) 2024.
World J Hepatol. Aug 27, 2024; 16(8): 1099-1110
Published online Aug 27, 2024. doi: 10.4254/wjh.v16.i8.1099
Published online Aug 27, 2024. doi: 10.4254/wjh.v16.i8.1099
Variable | Mild fibrosis (FIB-4 < 1.45), n = 50 | Moderate to severe fibrosis (FIB-4 ≥ 1.45), n = 19 | P value | OR | 95%CI |
Sex, n (%) | 0.479 | 0.681 | 0.234-1.978 | ||
Female | 19 (38.0) | 9 (47.4) | |||
Male | 31 (62.0) | 10 (52.6) | |||
Age at diagnosis (yr), mean ± SD | 40 ± 16 | 56 ± 11 | < 0.001a | - | - |
Age (yr), mean ± SD | 45 ± 16 | 63 ± 11 | < 0.001a | - | - |
BMI (kg/m2), mean ± SD | 26.5 ± 4.4 | 26.2 ± 4.9 | 0.800 | - | - |
Waist circumference (cm), mean ± SD | 94 ± 12 | 93 ± 14 | 0.898 | - | - |
Arterial hypertension, n (%) | 0.002a | 5.429 | 1.743-16.903 | ||
Yes | 12 (24.0) | 12 (63.2) | |||
No | 38 (76.0) | 7 (36.8) | |||
Type 2 DM, n (%) | 0.508 | 1.627 | 0.466-5.680 | ||
Yes | 9 (18.0) | 5 (26.3) | |||
No | 41 (82.0) | 14 (73.7) | |||
Dyslipidaemia, n (%) | 0.387 | 1.600 | 0.549-4.664 | ||
Yes | 18 (36.0) | 9 (47.4) | |||
No | 32 (64.0) | 10 (52.6) | |||
Obesity, n (%) | 1.000 | 0.945 | 0.260-3.435 | ||
Yes | 11 (22.0) | 4 (21.1) | |||
No | 39 (78.0) | 15 (78.9) | |||
Metabolic syndrome, n (%) | 0.586 | 1.361 | 0.448-4.135 | ||
Yes | 15 (30.0) | 7 (36.8) | |||
No | 35 (70.0) | 12 (63.2) | |||
Regular alcohol intake, n (%) | 0.028a | 3.328 | 1.107-10.003 | ||
Yes | 17 (34.0) | 12 (63.2) | |||
No | 33 (66.0) | 7 (36.8) | |||
AAT value at diagnosis (mg/dL), median | 71 | 58 | 0.060 | - | - |
FEV1 (%), mean ± SD | 94 ± 27 | 94 ± 36 | 0.944 | - | - |
DLCO, mL of CO/s/mmHg, median | 94 | 88 | 0.325 | - | - |
- Citation: Ferreira AI, Guimarães C, Macedo Silva V, Xavier S, Magalhães J, Cotter J. Alpha-1 antitrypsin deficiency and Pi*Z allele as important co-factors in the development of liver fibrosis. World J Hepatol 2024; 16(8): 1099-1110
- URL: https://www.wjgnet.com/1948-5182/full/v16/i8/1099.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i8.1099